Quanterix (QTRX)

The company is best known for Simoa, its single-molecule array platform, which is designed to detect proteins at levels that are often below the range of conventional immunoassays. Quanterix sells instruments, assay kits, consumables, and related software to pharmaceutical companies, academic laboratories, contract research organizations, and other research customers. Its menu includes assays used in neurology, inflammation, oncology, cardiology, and infectious disease research, with particular visibility in neurodegenerative disease biomarkers such as neurofilament light chain and phosphorylated tau.

Quanterix also operates an Accelerator Laboratory that provides assay development, sample testing, and clinical laboratory services. This service component allows customers to access the company’s technology without purchasing instruments and supports projects that may move from discovery into clinical development. The company has introduced laboratory developed tests, including tests associated with Alzheimer’s disease and neurological injury research, while continuing to position its platforms primarily around high-sensitivity biomarker measurement.

In addition to Simoa, Quanterix offers spatial biology capabilities through its SP-X imaging and analysis system. The business serves customers across North America, Europe, the Middle East, Africa, and Asia Pacific. Its market opportunity is tied to rising demand for precision medicine, biomarker-driven drug development, and earlier detection or monitoring of complex diseases.